Guide · 7 min
From Pharmacy Shelf to Specialist Clinic: How the NHS Hayfever Ladder Actually Works
What you can buy, what you can be prescribed, and when it's time to ask for more help
In short
NHS referral criteria for specialist allergy services are not uniformly codified at a national level but are guided primarily by NICE guidelines (notably CG134 for anaphylaxis) and local trust protocols, with referral indicated for severe or complex cases including anaphylaxis, venom allergy, drug…
From antihistamines on the pharmacy shelf to immunotherapy at a specialist clinic — a clear-eyed guide to your options on the NHS
Every spring, millions of people in the UK do the same quiet calculation: Is this bad enough to see a doctor? Often the answer is no — a trip to Boots, a box of cetirizine, and a resigned acceptance that the next few months will involve a lot of tissue. But sometimes that answer should be yes, and the system that's supposed to help isn't always easy to read.
If your hayfever has ever made you cancel plans, miss work, or lie awake with a nose that refuses to cooperate, you deserve to understand what the NHS actually offers you — and where the gaps are. Because there are real gaps, and knowing about them in advance means you're not discovering them at the worst possible moment.
The Science: How NHS Hayfever Care Is Structured
NHS treatment for allergic rhinitis (the clinical name for hayfever) follows a stepwise logic: start simple, escalate only when needed. It sounds sensible, and largely it is — but the steps aren't always clearly signposted, and where you live can matter as much as how severe your symptoms are.
What you can get without a prescription
The first line of defence is remarkably well-stocked at any pharmacy. Second-generation antihistamines — cetirizine, loratadine, and fexofenadine (120mg) — are all available over the counter, and these are genuinely effective medications, not consolation prizes. They work by competitively blocking H1 histamine receptors, blunting the sneezing, itching, and watery eyes that histamine triggers when you encounter pollen.
Intranasal corticosteroids, which many specialists consider the most effective single treatment for nasal symptoms, are also now available without prescription. Fluticasone propionate, beclometasone, and mometasone furoate nasal sprays can all be bought off the shelf. These work differently to antihistamines — rather than blocking a single mediator, they reduce the underlying eosinophilic inflammation and mast cell activity in your nasal mucosa. That's why consistent daily use through your season tends to outperform taking a tablet when symptoms strike (Bridgeman, 2017). Sodium cromoglicate eye drops and short-term decongestant nasal sprays round out the OTC toolkit.
It's worth knowing that NHS England guidance now actively discourages GPs from prescribing these OTC-available treatments on the NHS for adults with mild-to-moderate disease. This isn't the NHS abandoning you — it's a policy shift toward self-care for conditions with good off-the-shelf solutions. But it does mean that if you're managing mild symptoms, the expectation is that you'll manage them yourself.
When a GP gets involved
If OTC treatments aren't cutting it, your GP has access to prescription-only options that can make a meaningful difference. Azelastine nasal spray and combination products — particularly the azelastine plus fluticasone propionate combination — are prescription-only and represent a genuine step up in symptom control for people who've plateaued on pharmacy options. Higher-strength formulations of some corticosteroids are also available on prescription.
The GP is also the gateway to specialist care — but the threshold for referral matters. For conditions like anaphylaxis, any occurrence warrants urgent specialist referral under NICE guideline CG134. For allergic rhinitis, it's different: referral to a specialist allergy clinic is generally reserved for cases that haven't responded to maximal primary care treatment (Ewan & Durham, 2002; Kasternow & Karim, 2016). In practice, that means demonstrating you've tried antihistamines and intranasal corticosteroids adequately before a referral to a specialist is considered appropriate.
Immunotherapy: the disease-modifying option
Allergen immunotherapy (AIT) is in a different category to everything else discussed so far. While antihistamines and corticosteroids manage symptoms, immunotherapy works on the underlying immune mechanism — gradually retraining your immune system to tolerate allergens rather than overreacting to them.
The mechanism is genuinely impressive: AIT shifts the Th2-dominant immune response that drives allergic disease, increases regulatory T-cell activity, and induces allergen-specific tolerance. The effect is disease-modifying, not just symptom-suppressing — which is why treatment typically runs for three years and why it's delivered under specialist supervision.
On the NHS, both subcutaneous immunotherapy (SCIT, given as injections in a clinic) and sublingual immunotherapy (SLIT, taken as drops or tablets at home) are available. Several SLIT products have NICE approval — including Grazax for grass pollen, Acarizax for house dust mite, and Itulazax for tree pollen — and can be prescribed at specialist allergy clinics. SCIT is administered in hospital settings with resuscitation facilities on hand (Rajakulasingam et al., 2018).
To access immunotherapy on the NHS, you typically need: a GP referral to a specialist allergy clinic, documented failure of stepwise pharmacotherapy, and confirmed sensitisation via skin prick testing or specific IgE blood testing. That's a meaningful set of requirements — and deliberately so, given the resource intensity of the treatment.
What This Means for You
If your hayfever is mild — a few weeks of sneezing, manageable with an antihistamine — the NHS system works reasonably well for you, even if the GP isn't involved. The OTC options are good, and the guidance to self-manage is clinically reasonable.
If your hayfever is significantly affecting your quality of life and pharmacy treatments haven't delivered adequate control, the system is harder to navigate. You'll need to demonstrate that you've genuinely tried first-line treatments before a referral to a specialist will be taken seriously. This isn't a bureaucratic obstacle for its own sake — it's risk stratification, designed to direct limited specialist capacity toward those who need it most. But it does mean you benefit from being methodical: keep a note of what you've tried, at what dose, for how long, and what effect it had. That information matters when you're sitting in a GP appointment.
If you're interested in immunotherapy, be prepared for a longer journey. Access to specialist allergy services varies significantly by where you live — commissioning is devolved to individual Integrated Care Boards (ICBs), and the geographic inequity in service availability is well-documented in the literature (Erlewyn-Lajeunesse et al., 2025; Diwakar et al., 2017). Some areas have well-resourced specialist clinics; others have waiting lists that stretch into years, or limited services that don't offer immunotherapy at all.
The Evidence Landscape: What We Know and Where the Gaps Are
The clinical evidence for individual treatments is reasonably strong — intranasal corticosteroids and antihistamines are among the most studied interventions in primary care. The evidence for allergen immunotherapy's disease-modifying effect is compelling, with multiple systematic reviews supporting its efficacy in allergic rhinitis.
Where the evidence is weaker is in understanding the system itself. There are no published peer-reviewed studies that comprehensively quantify UK-wide referral rates, rejection rates, or patient outcomes following specialist allergy referral (Egner et al., 2018). We know from service surveys and expert commentary that demand for specialist allergy services substantially exceeds capacity — but we don't have precise, current data on how bad the gap is or how post-2021 Integrated Care System restructuring has affected access pathways (Ewan & Durham, 2002).
The BSACI's BRIT registry is beginning to generate real-world data on immunotherapy access inequalities (Erlewyn-Lajeunesse et al., 2025), but it's early days. We also lack robust evidence on paediatric access pathways and the comparative cost-effectiveness of SCIT versus SLIT within NHS commissioning frameworks.
What this means in practice: the clinical guidance on what to use is solid. The guidance on how to get it through the NHS is patchier, and your experience will depend partly on where you live and partly on how well you can advocate for yourself.
What Haelo Recommends
1. Start with intranasal corticosteroids, not just antihistamines. If you're only using antihistamines, you may be leaving significant symptom control on the table. Intranasal corticosteroids (available OTC) are considered more effective for nasal symptoms and work best when used consistently throughout your season, not just on bad days. Begin a few weeks before your typical season starts.
2. Keep a treatment diary before your GP appointment. If OTC options aren't working, a GP referral is the next step — but you'll need to show you've tried first-line treatments properly. Note what you used, the dose, how consistently, for how long, and what happened. This is the evidence a GP needs to justify a referral onward.
3. Ask specifically about combination therapy. If you've tried antihistamines and intranasal corticosteroids separately without adequate relief, ask your GP about the azelastine/fluticasone combination nasal spray. It's prescription-only but represents a meaningful step up and is sometimes overlooked.
4. If immunotherapy interests you, ask early. Given the access pressures on NHS specialist allergy services, the earlier in your journey you raise interest in immunotherapy with your GP, the better. Waiting lists can be long, and knowing your local commissioning situation sooner gives you more options.
5. Know your ICB. Your access to specialist services — including immunotherapy — may depend significantly on which Integrated Care Board covers your area. If you're getting pushback on a referral that seems clinically justified, it's worth asking specifically which services your ICB commissions and whether a referral to a neighbouring trust is possible.
6. Don't wait for crisis. The NHS system is designed to respond to need, but the allergy services that can make the biggest difference — specialist assessment, immunotherapy — require planning and patience. If your hayfever is substantially affecting your life, start the conversation with your GP before your season peaks, not during it.
The NHS has real treatments that can make a real difference to how you experience hayfever — from pharmacy staples to disease-modifying immunotherapy. Understanding the system helps you move through it more effectively. Haelo is here to help you track what's working, build your symptom history, and walk into every appointment better informed.
The evidence
What the research actually says
Each answer below is drawn from a graded research review. Confidence reflects the strength of the underlying evidence, not how confident we feel about it.
What are the NHS referral criteria for specialist allergy services?
NHS referral criteria for specialist allergy services are not uniformly codified at a national level but are guided primarily by NICE guidelines (notably CG134 for anaphylaxis) and local trust protocols, with referral indicated for severe or complex cases including anaphylaxis, venom allergy, drug hypersensitivity, recurrent angioedema, and rhinitis or urticaria resistant to maximal primary care therapy. For allergic rhinitis specifically, referral to specialist allergy services is reserved for cases unresponsive to first-line treatments such as antihistamines and intranasal corticosteroids, distinguishing it from higher-acuity conditions like anaphylaxis where any occurrence triggers referral. The evidence consistently highlights chronic underprovision of NHS specialist allergy services, with access remaining geographically inequitable and demand substantially exceeding capacity.
How it works
Referral thresholds are clinically risk-stratified: conditions involving systemic immune-mediated reactions (IgE-mediated anaphylaxis, C1-inhibitor deficiency) warrant urgent specialist input for definitive diagnosis, allergen immunotherapy candidacy, and adrenaline auto-injector provision, whereas rhinitis management is stepwise, escalating to specialist care only when empirical pharmacotherapy has failed and quality of life or diagnostic uncertainty justifies resource use.
Confidence: moderate
Which hayfever treatments are available over the counter vs prescription in the UK?
In the UK, a broad range of hay fever treatments are available over the counter (OTC), including second-generation oral antihistamines (cetirizine, loratadine, fexofenadine 120mg), intranasal corticosteroids (fluticasone propionate, beclometasone, mometasone furoate nasal sprays), sodium cromoglicate eye drops, and short-term decongestant nasal sprays. Prescription-only treatments include azelastine nasal spray, combination products (e.g., azelastine plus fluticasone propionate), higher-strength formulations, and specialist-administered immunotherapy (sublingual or subcutaneous). NHS England guidance advises GPs against routinely prescribing OTC-available treatments on the NHS for adults, reflecting a policy shift toward self-care for mild-to-moderate disease.
How it works
Intranasal corticosteroids reduce local eosinophilic inflammation and mast cell activity in nasal mucosa, making them the most effective single-agent treatment for nasal symptoms, while antihistamines competitively block H1 receptors to reduce histamine-mediated symptoms; immunotherapy uniquely modifies the underlying Th2-skewed immune response through allergen desensitisation, which is why it remains in specialist hands.
Confidence: moderate
How do UK patients access immunotherapy on the NHS?
UK NHS patients access allergen immunotherapy (AIT) for allergic rhinitis via GP referral to specialist allergy clinics following demonstrated failure of stepwise pharmacotherapy (intranasal corticosteroids, antihistamines, leukotriene antagonists), with eligibility requiring confirmed sensitisation via SPT or specific IgE. Both SCIT and SLIT are available on the NHS, with NICE-approved SLIT products (e.g., Grazax, Acarizax, Itulazax) prescribable in allergy clinics and SCIT delivered in hospital settings with resuscitation facilities. However, access is significantly inequitable, with commissioning devolved to individual ICBs, resulting in substantial geographic variation in service availability.
How it works
AIT modifies the underlying allergic immune response by inducing allergen-specific tolerance, shifting the Th2-dominant response and increasing regulatory T-cell activity, thereby reducing symptoms and altering disease course rather than merely suppressing them. This disease-modifying effect justifies the 3-year treatment commitment and specialist oversight required for safe administration.
Confidence: moderate
Where the evidence runs out
No peer-reviewed studies directly quantify UK-wide referral rates, rejection rates, or patient outcomes following specialist allergy referral, and there is no centralized NHS England commissioning policy document governing allergy referrals uniformly across trusts. The evidence base largely reflects service surveys and expert opinion from 2000–2022, with limited data on post-2021 commissioning reforms or the impact of integrated care system restructuring on referral pathways. The academic literature reviewed is predominantly non-UK-specific or pre-2020, meaning recent UK-specific reclassification decisions (e.g., fluticasone propionate reclassification in December 2025) and evolving NHS prescribing policies are not directly validated by peer-reviewed studies in this dataset. Additionally, evidence on real-world patient outcomes following NHS OTC-restriction policies in the UK is limited. Quantitative data on NHS waiting times and the precise extent of ICB-level commissioning variation are largely absent from the peer-reviewed literature, with the BRIT registry (2025) beginning to address real-world access inequalities but not yet fully published. Evidence on paediatric access pathways, multi-allergen protocols, and the comparative cost-effectiveness of SCIT versus SLIT within NHS commissioning frameworks remains limited.
References
- 1.Erlewyn-Lajeunesse M, Villa L, Shaikh S et al. · 2025 · Inequalities in Access to Specialist Allergy Services in the United Kingdom: A Report From the BSACI Registry for Immunotherapy (BRIT)
- 2.Ewan P, Durham S · 2002 · NHS allergy services in the UK: proposals to improve allergy care
- 3.Kasternow B, Karim M · 2016 · Introduction to drug allergy, and whom to refer for specialist assessment?
- 4.Rajakulasingam R, Farah N, Huber P et al. · 2018 · Practice and safety of allergen-specific immunotherapy for allergic rhinitis in the UK national health service: A report of 'real world' clinical practice
- 5.Diwakar L, Cummins C, Lilford R et al. · 2017 · Systematic review of pathways for the delivery of allergy services
- 6.Bridgeman MB · 2017 · Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis
- 7.Price D, Scadding G, Bachert C et al. · 2016 · UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study
- 8.Levy M, Walker S, Woods A · 2009 · Service evaluation of a UK primary care-based allergy clinic: quality improvement report
This article is general information about hayfever, not medical advice. It should not replace guidance from your GP, pharmacist or allergy specialist — particularly if you are pregnant, treating a child, or managing asthma alongside hayfever. Read our medical disclaimer.
